Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of TM5614 for systemic sclerosis-associated interstitial lung disease on background immunosuppression
jRCT2021230022Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2023
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TM5614 in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in percent predicted forced vital capacity. Started Sep 2023; status: completed.
02
Drugs
TM5614
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on jRCT2021230022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230022.